Core Insights - Illumina's shares increased by 3.3% to close at $134.78, with notable trading volume, and a total gain of 9.4% over the past four weeks [1][2] Company Performance - Illumina is expected to report quarterly earnings of $1.22 per share, reflecting a year-over-year increase of 41.9%, while revenues are projected to be $1.1 billion, a slight decrease of 0.3% from the previous year [3] - The consensus EPS estimate for Illumina has been revised marginally higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] Industry Context - Illumina operates within the Zacks Medical - Biomedical and Genetics industry, where Regeneron, another company in the same sector, saw a 2.6% increase in its stock price, closing at $767.96, with a 1.6% return over the past month [4] - Regeneron's consensus EPS estimate has decreased by 2.8% over the past month to $10.48, representing a year-over-year decline of 13.2%, and it currently holds a Zacks Rank of 3 (Hold) [5]

分组1 - Illumina reported quarterly earnings of $1.34 per share, exceeding the Zacks Consensus Estimate of $1.16 per share, and showing an increase from $1.14 per share a year ago, resulting in an earnings surprise of +15.52% [1] - The company achieved revenues of $1.08 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.73%, with year-ago revenues also at $1.08 billion [2] - Illumina has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has underperformed, losing about 28.9% since the beginning of the year, while the S&P 500 has gained 17.2% [3] - The current consensus EPS estimate for the coming quarter is $1.18 on revenues of $1.1 billion, and for the current fiscal year, it is $4.49 on revenues of $4.26 billion [7] - The Medical - Biomedical and Genetics industry, to which Illumina belongs, is currently in the top 38% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]